These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 17476720)

  • 1. A brief review of Phase 1 and Clinical Pharmacology statistics in clinical drug development.
    Patterson SD; Jones B
    Pharm Stat; 2007; 6(2):79-87. PubMed ID: 17476720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 25-year review of sequential methodology in clinical studies.
    Todd S
    Stat Med; 2007 Jan; 26(2):237-52. PubMed ID: 17139691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo pharmacology in drug discovery and development.
    Svendsen O; Ahnfelt-Rønne I; Vanhoutte P
    Basic Clin Pharmacol Toxicol; 2006 Aug; 99(2):89-90. PubMed ID: 16918707
    [No Abstract]   [Full Text] [Related]  

  • 4. Globalization of quantitative pharmacology: first international symposium of quantitative pharmacology in drug development and regulation.
    Barrett JS; Shi J; Xie HT; Huang XH; Fossler MJ; Sun RY
    J Clin Pharmacol; 2008 Jul; 48(7):787-92. PubMed ID: 18490494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experiences with learning and confirming in drug and biological development.
    Patterson SD
    Clin Pharmacol Ther; 2010 Aug; 88(2):161-3. PubMed ID: 20648033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. If a drug deemed 'safe' in nonclinical tests subsequently prolongs QT in phase 1 studies, how can its sponsor convince regulators to allow development to proceed?
    Shah RR
    Pharmacol Ther; 2008 Aug; 119(2):215-21. PubMed ID: 18455801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential designs for ordinal phase I clinical trials.
    Liu G; Rosenberger WF; Haines LM
    Biom J; 2009 Apr; 51(2):335-47. PubMed ID: 19358220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical cross-over trials in phase I.
    Senn S; Ezzet F
    Stat Methods Med Res; 1999 Sep; 8(3):263-78. PubMed ID: 10636338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of pharmacogenomics for drug development.
    Kirk RJ; Hung JL; Horner SR; Perez JT
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1484-97. PubMed ID: 18849536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefit and risk assessment in drug development and utilization: a role for clinical pharmacology.
    Honig P
    Clin Pharmacol Ther; 2007 Aug; 82(2):109-12. PubMed ID: 17632530
    [No Abstract]   [Full Text] [Related]  

  • 12. Statistics in pharmacology.
    Spina D
    Br J Pharmacol; 2007 Oct; 152(3):291-3. PubMed ID: 17618311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A SAS-based solution to evaluate study design efficiency of phase I pediatric oncology trials via discrete event simulation.
    Barrett JS; Jayaraman B; Patel D; Skolnik JM
    Comput Methods Programs Biomed; 2008 Jun; 90(3):240-50. PubMed ID: 18276034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Introduction of quantitative methods in pharmacology and clinical pharmacology: a historical overview.
    Atkinson AJ; Lalonde RL
    Clin Pharmacol Ther; 2007 Jul; 82(1):3-6. PubMed ID: 17571065
    [No Abstract]   [Full Text] [Related]  

  • 15. [Experience with phase I of clinical pharmacology in the registration of drugs].
    von Eickstedt KW
    Arzneimittelforschung; 1973 Nov; 23(11):Suppl:1677-8. PubMed ID: 4801617
    [No Abstract]   [Full Text] [Related]  

  • 16. PK/PD modelling and simulations: utility in drug development.
    Rajman I
    Drug Discov Today; 2008 Apr; 13(7-8):341-6. PubMed ID: 18405847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translation of innovative designs into phase I trials.
    Rogatko A; Schoeneck D; Jonas W; Tighiouart M; Khuri FR; Porter A
    J Clin Oncol; 2007 Nov; 25(31):4982-6. PubMed ID: 17971597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombotic drug development for atrial fibrillation: proceedings, Washington, DC, July 25-27, 2005.
    Jackson K; Gersh BJ; Stockbridge N; Fleming TR; Temple R; Califf RM; Connolly SJ; Wallentin L; Granger CB;
    Am Heart J; 2008 May; 155(5):829-40. PubMed ID: 18440329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A parallel phase I/II clinical trial design for combination therapies.
    Huang X; Biswas S; Oki Y; Issa JP; Berry DA
    Biometrics; 2007 Jun; 63(2):429-36. PubMed ID: 17688495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design issues in dose-finding Phase I trials for combinations of two agents.
    Fan SK; Venook AP; Lu Y
    J Biopharm Stat; 2009; 19(3):509-23. PubMed ID: 19384692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.